Article Text

other Versions

PDF
Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
  1. Pontus Berglund (pontus.berglund{at}med.lu.se)
  1. Center for Molecular Pathology, Dep. of Lab. Med., Lund University, Malmö University Hospital, Sweden
    1. Maria Stighall (maria.stighall{at}gmail.com)
    1. Center for Molecular Pathology, Dep. of Lab. Med., Lund University, Malmö University Hospital, Sweden
      1. Karin Jirström (karin.jirstrom{at}med.lu.se)
      1. Center for Molecular Pathology, Dep. of Lab. Med., Lund University, Malmö University Hospital, Sweden
        1. Lisa Rydén (lisa.ryden{at}med.lu.se)
        1. Department of Surgery, Helsingborgs Lasarett, Helsingborg, Sweden
          1. Mårten Fernö (marten.ferno{at}med.lu.se)
          1. Department of Oncology, Lund University Hospital, Lund, Sweden
            1. Bo Nordenskjöld (bo.nordenskjold{at}ibk.liu.se)
            1. Department of Oncology, Linköping University Hospital, Linköping, Sweden
              1. Göran Landberg (goran.landberg{at}med.lu.se)
              1. Center for Molecular Pathology, Dep. of Lab. Med., Lund University, Malmö University Hospital, Sweden

                Abstract

                Aim: This study investigates the prognostic value of cyclin E in relation to tumour growth pattern by analysing stage II primary breast cancers from premenopausal women not subjected to any further adjuvant treatment. In addition, the value of cyclin E as a predictor of tamoxifen response was analysed, by comparing untreated and treated patients with oestrogen receptor positive tumours.

                Methods: Breast cancer samples, assembled in tissue microarrays, were immunohistochemically stained for cyclin E and evaluated regarding the presence of nuclear staining. The overall growth characteristics of each tumour were assessed using whole tissue sections.

                Results: Tumours displaying a pushing margin phenotype were strongly associated with high cyclin E levels, lymph node negative disease, a high histological grade, ER negativity, and exhibited a better prognosis compared to tumours with an infiltrative growth pattern. In the total cohort of non-treated patients (N=187), cyclin E was not associated with recurrence free survival (RFS). However, when analysing the subgroup of tumours lacking a pushing growth pattern (N=141), cyclin E was significantly associated with RFS, independent of histological grade and node status. There was no significant difference in tamoxifen response with regard to different cyclin E levels.

                Conclusion: The prognostic value of cyclin E in premenopausal breast cancer is limited to patients with breast carcinomas exhibiting an exclusively infiltrative growth pattern. This limitation could be explained by the presence of a small but distinct subgroup of cyclin E-high breast cancers with a pushing margin phenotype and a more favourable outcome.

                • breast cancer
                • cyclin E
                • medullary carcinoma
                • tamoxifen
                • tumour growth pattern

                Statistics from Altmetric.com

                Request permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.